Endometriosis Treatment Success Rate: What to Expect and How Long It Takes

• "Success" has several meanings in endometriosis: less pain, achieving pregnancy, and keeping the disease from coming back. The right goal is the one that matters most to you right now.
• Hormonal medicines (the pill, dienogest, the Mirena IUS) control endometriosis pain in roughly 60 to 80 percent of women, but take 3 to 6 months for full effect.
• Laparoscopic surgery improves pain in about 70 to 80 percent of women; without hormonal treatment afterwards, symptoms return in 40 to 50 percent within 5 years.
• IVF live birth rates with endometriosis are broadly similar to other causes of infertility once adjusted for age: around 35 to 45 percent per cycle under 35, falling to 10 to 15 percent over 40.
• Endometriosis is a chronic condition. Durable control and pregnancy are realistic goals, but a true "cure" before menopause is uncommon, so most plans are long-term.
• See a gynaecologist with endometriosis expertise if first-line treatment fails, if you have a large ovarian cyst, or if you are trying to conceive.

Endometriosis affects different women in different ways, so there is no single yardstick for success. The first step in any treatment plan is to decide what you most want it to achieve, because the best choice for pain is not always the best choice for fertility.

There are four ways to measure success, and most women care about more than one over their lifetime:

• Pain control. If pain is your main problem and pregnancy is not on the agenda right now, success means fewer painful periods (Painful Periods (Dysmenorrhea) in India: Why It Hurts and What Helps), less daily pelvic pain, less pain during sex, and better quality of life, often measured with tools like the EHP-30 questionnaire or a simple pain score.
• Fertility. If having a baby is the priority, success is measured in pregnancy and live birth rates after a given treatment.
• Long-term control. Endometriosis tends to return after surgery and after hormonal treatment is stopped, so a good plan keeps recurrence low over years, not just months.
• Protecting your ovaries. Repeated surgery or large endometriomas can lower your egg reserve, so a successful plan controls today's symptoms without sacrificing future fertility.

Combined oral contraceptive pills (COCs), which contain oestrogen plus a progestin, are the most widely used first treatment for endometriosis pain. They work by stopping ovulation, lightening periods, cutting the prostaglandins that drive cramps, and slowly shrinking endometriosis deposits over months.

Reviews summarised by ESHRE and Cochrane show COCs reduce period pain, pain during sex and chronic pelvic pain in around 60 to 80 percent of women within 3 to 6 cycles of consistent use. Taking the pill continuously (skipping the placebo week) or in extended cycles (3 to 4 packs back-to-back) is now often preferred over the standard 21/7 pattern, because fewer bleeds usually means less pain.

In India, COCs are among the most affordable options. Generic brands such as Mala-D, Femilon, Yasmin, Yamini, Krimson 35 and Diane 35 cost roughly Rs 10 to 300 per month, and Mala-N is free under government family-planning programmes.

Common side effects include breakthrough bleeding (most likely in the first 3 months, and with continuous use), nausea, breast tenderness, mood changes and headache. There is a small increase in the risk of blood clots. COCs are not suitable if you have had a clot, migraine with aura, uncontrolled high blood pressure, or if you smoke and are over 35. Our guide to the pill and other birth-control options in India and what side effects are normal versus worth acting on covers this in detail.

If standard cyclic pills do not control your pain, switching to a continuous regimen often helps. If you are still struggling after 3 to 6 months, the next step is usually a progestin like dienogest, a GnRH-based medicine, or surgical assessment. Note that COCs prevent pregnancy, so they must be stopped 1 to 3 months before trying to conceive to let ovulation return.

Progestin-only treatment is the main second-line option for endometriosis pain, and a good first choice for women who cannot take combined pills (smokers over 35, migraine with aura, history of clots) or who did not respond well to COCs.

Dienogest 2 mg daily (brands include Visanne and Indian generics such as Endogest, roughly Rs 800 to 1,500 per month) is specifically licensed for endometriosis and has the strongest evidence. Trials show it reduces pain by around 50 to 70 percent within 12 to 24 weeks, with the benefit holding over years of continuous use. Taken without a break, it usually leads to no periods or very light bleeding within 3 to 6 months. Side effects can include early breakthrough bleeding, breast tenderness, mood changes and weight gain in some women, and long-term safety data extend to 5 to 10 years.

Other progestins used in India include norethisterone acetate (Primolut-N, about Rs 30 to 150 per month), oral medroxyprogesterone (Provera) and the 3-monthly Depo-Provera injection.

The levonorgestrel-releasing intrauterine system, or Mirena IUS (around Rs 12,000 to 20,000 for the device and fitting), is especially useful when endometriosis comes with heavy periods or Adenomyosis vs Endometriosis: Differences, Diagnosis & Treatment. It provides 5 years of treatment and reduces pain substantially in 70 to 80 percent of users. Our comparison of the copper IUD and Mirena in India explains how it works.

For a younger woman who also wants long-term contraception, the Mirena is increasingly recommended as a "two-for-one" solution. Like the pill, all progestins prevent pregnancy and must be stopped before trying to conceive. Overall, progestin therapy is well tolerated and offers a long-term alternative to repeated surgery for many women.

GnRH medicines create a temporary, reversible "medical menopause" that strongly suppresses endometriosis. They are usually reserved for severe pain that COCs or progestins have not controlled, or used before IVF or surgery.

GnRH agonists such as leuprolide (Lupride Depot, given monthly or 3-monthly, about Rs 4,500 to 15,000 per dose in India) and goserelin (Zoladex) relieve pain in 80 to 85 percent of women within 1 to 3 months. The trade-off is menopausal side effects: hot flushes, vaginal dryness, mood and sleep changes, and bone density loss of around 5 to 6 percent in the first 6 months. For this reason, these drugs are usually limited to 6 months on their own, or up to 12 to 24 months with "add-back" therapy, a low dose of oestrogen plus progestin (or tibolone) that protects bone and eases hot flushes without cancelling the benefit.

Newer GnRH antagonists, elagolix (Orilissa) and relugolix, work directly without the initial flare of agonists, are taken as a daily tablet, and are often combined with add-back hormones. They are approved in the US and parts of Europe and are gradually becoming available in India through specialist channels.

GnRH treatment is also used before IVF in severe disease (the "ultra-long" protocol), which some studies suggest improves outcomes. Aromatase inhibitors such as letrozole are occasionally used off-label for pain that has not responded to first- and second-line treatment, under specialist supervision.

Endometriosis pain often responds best to a combined approach. These options sit alongside hormonal or surgical treatment rather than replacing them.

For period pain, NSAIDs are first-line: ibuprofen 400 mg three times a day, naproxen, or mefenamic acid (Meftal), ideally started a day or two before your period and continued through the heavy days. They reduce cramps by 50 to 70 percent but do not treat the disease itself. For long-standing nerve-type pelvic pain, doctors sometimes add pregabalin, gabapentin or low-dose amitriptyline.

Non-drug approaches matter too:

• Pelvic floor physiotherapy helps the muscle tightness and painful sex that are common in chronic pelvic pain. It is available through women's-health physiotherapists in India (roughly Rs 800 to 2,500 per session, usually 8 to 12 sessions).
• Mind-body care such as CBT, mindfulness and yoga has evidence for chronic pelvic pain.
• Other measures with some support include acupuncture, TENS, heat, a low-FODMAP diet if you also have IBS-like symptoms, and correcting vitamin D deficiency, which is very common in Indian women.

Fertility outcomes depend on the stage of disease, your age, your egg reserve and any previous surgery. The detailed picture is in our guide to endometriosis and infertility; here is the summary.

For mild disease (stage I to II) with otherwise unexplained infertility, laparoscopic surgery modestly improves pregnancy rates. For moderate-to-severe disease (stage III to IV), surgery achieves natural pregnancy in around half of carefully selected women within 12 to 18 months, with most of the benefit in the first year to 18 months.

IUI (intrauterine insemination) with ovarian stimulation gives a pregnancy rate of about 11 to 15 percent per cycle in mild disease, but it is not effective for stage III to IV.

IVF is the most effective treatment for moderate-to-severe endometriosis. Live birth rates per cycle are broadly:

• Under 35: around 35 to 45 percent
• 35 to 37: around 30 to 35 percent
• 38 to 40: around 20 to 25 percent
• Over 40: around 10 to 15 percent

Knowing how long each treatment needs to work prevents premature switching and unnecessary disappointment.

• Hormonal medicines (the pill, dienogest): some relief in the first 1 to 2 cycles, but full benefit needs 3 to 6 months because the deposits take time to shrink. Breakthrough bleeding in the first 3 months is normal and usually settles.
• GnRH agonists: pain eases within 4 to 8 weeks, after the brief initial flare.
• Laparoscopic surgery: 1 to 2 weeks to recover from the operation, with pain often improving immediately for deposits and cysts that were removed and settling further over 3 to 6 months. Full assessment takes 6 to 12 months.
• IVF: roughly 6 to 8 weeks from the start of a cycle to the pregnancy test, with a 2-week wait at the end. If a cycle does not work, the next usually starts a couple of cycles later, so cumulative success can take 6 to 12 months.
• Conceiving naturally after surgery: allow 4 to 6 weeks to recover, then the best window is the first 12 to 18 months.
• Non-hormonal pain care (physiotherapy, CBT, nerve-pain medicines): allow 8 to 12 weeks to judge the effect.

Endometriosis needs medical care rather than self-management, and certain situations call for prompt or specialist review:

• Period or pelvic pain that disrupts work, study or sleep, or that painkillers no longer control
• Pain during sex, or pain when passing urine or stool, especially during periods
• You have been trying to conceive for 12 months (or 6 months if you are over 35) without success
• A known ovarian cyst that is enlarging, or new sudden severe pelvic pain (see our guide to ovarian cysts and when to worry)
• First-line treatment has not helped after 3 to 6 months, or symptoms have returned after surgery
• Low mood, anxiety or hopelessness linked to living with pain

If first-line treatment does not deliver, there are still clear next steps, and seeking another opinion is sensible rather than a sign of giving up.

For pain that does not respond, switching class often helps: COC to dienogest, dienogest to a GnRH agonist with add-back, or adding the Mirena. For recurrence after surgery, a repeat laparoscopy by an experienced excisional surgeon may be appropriate, though repeated operations gradually reduce egg reserve and are avoided where possible.

For fertility that does not succeed after several IVF cycles, options include donor eggs (when age or egg reserve is the limiting factor), gestational surrogacy (for uterine factors) or other routes to parenthood including adoption.

Emerging treatments under study include the newer GnRH antagonists now reaching India, and various surgical refinements. Throughout, mental health support and patient communities such as the Endometriosis Society of India can make a real difference. As women approach midlife, it also helps to know that symptoms often ease around What Is Perimenopause? Navigating the Transition with Confidence as oestrogen falls. ESHRE and FOGSI both stress patient-centred, shared decision-making, so ask questions, seek other opinions, and advocate for a plan that fits your priorities.

• ESHRE Guideline: Endometriosis (2022)
• NICE Guideline NG73: Endometriosis – diagnosis and management
• ACOG: Endometriosis (FAQ and Practice Guidance)
• WHO: Endometriosis fact sheet
• Cochrane Review: Long-term hormonal therapy after surgery for endometriosis
• NHS: Endometriosis – Treatment